Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Polaryx Therapeutics, Inc. (PLYX)
Company Research
Source: GlobeNewswire
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces its participation in two upcoming events supporting the Krabbe disease community. These events reflect Polaryx’s ongoing commitment to advancing research and strengthening engagement with patients, caregivers, and clinicians. 2026 Krabbe Translational Research Network Members of the Polaryx executive team, including Dr. Lisa Bollinger, Chief Medical Officer, Dr. Shrijay Vijayan, Chief Scientific and Business Development Officer, and Dr. Minsu Kang, Director of Regulatory and Clinical Affairs, will attend the 2026 Krabbe Translational Research Network (KTRN) meeting taking place March 18-20, 2026 in Minneapolis, Minn. Presented by the Rosenau Family Research Foundation, the KTRN meeting is dedicated to accelerating Krabbe research and engage
Show less
Read more
Impact Snapshot
Event Time:
PLYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLYX alerts
High impacting Polaryx Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLYX
News
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)GlobeNewswire
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders [Yahoo! Finance]Yahoo! Finance
- Polaryx Therapeutics (PLYX) is now covered by Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage DisordersGlobeNewswire
PLYX
Sec Filings
- 2/20/26 - Form 4
- 2/5/26 - Form SCHEDULE
- 2/2/26 - Form 424B4
- PLYX's page on the SEC website